GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » Other Operating Expense

Cyclopharm (ASX:CYC) Other Operating Expense : A$6.37 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Other Operating Expense?

Cyclopharm's Other Operating Expense for the six months ended in Dec. 2023 was A$5.48 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$6.37 Mil.

Cyclopharm's quarterly Other Operating Expense declined from Dec. 2022 (A$5.58 Mil) to Jun. 2023 (A$0.90 Mil) but then increased from Jun. 2023 (A$0.90 Mil) to Dec. 2023 (A$5.48 Mil).

Cyclopharm's annual Other Operating Expense declined from Dec. 2021 (A$6.14 Mil) to Dec. 2022 (A$6.08 Mil) but then increased from Dec. 2022 (A$6.08 Mil) to Dec. 2023 (A$6.37 Mil).


Cyclopharm Other Operating Expense Historical Data

The historical data trend for Cyclopharm's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Other Operating Expense Chart

Cyclopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.22 5.35 6.14 6.08 6.37

Cyclopharm Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.40 0.50 5.58 0.90 5.48

Cyclopharm Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$6.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclopharm Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclopharm (ASX:CYC) Business Description

Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines